Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.

Staehler M, Motzer RJ, George DJ, Pandha HS, Donskov F, Escudier B, Pantuck AJ, Patel A, DeAnnuntis L, Bhattacharyya H, Ramaswamy K, Zanotti G, Lin X, Lechuga M, Serfass L, Paty J, Ravaud A.

Ann Oncol. 2018 Oct 1;29(10):2098-2104. doi: 10.1093/annonc/mdy329.

PMID:
30412222
2.

Phase III Trial of Adjuvant Sunitinib in Patients With High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Donskov F, Escudier B, Li S, Casey M, Valota O, Laguerre B, Pantuck AJ, Pandha H, Patel A, Lechuga MJ, Ravaud A.

Clin Cancer Res. 2018 Nov 6. pii: clincanres.1724.2018. doi: 10.1158/1078-0432.CCR-18-1724. [Epub ahead of print]

PMID:
30401688
3.

Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR).

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A.

Eur Urol. 2018 Oct 11. pii: S0302-2838(18)30748-6. doi: 10.1016/j.eururo.2018.10.007. [Epub ahead of print]

PMID:
30318330
4.

Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.

Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM.

Clin Genitourin Cancer. 2018 Sep 12. pii: S1558-7673(18)30384-7. doi: 10.1016/j.clgc.2018.09.005. [Epub ahead of print]

PMID:
30287223
5.

Distress in patients with renal cell carcinoma: a curious gap in knowledge.

Bergerot CD, Battle D, Staehler MD, Pal SK.

BJU Int. 2018 Sep 25. doi: 10.1111/bju.14564. [Epub ahead of print] No abstract available.

PMID:
30253048
6.

A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations.

Bex A, Albiges L, Staehler M, Bensalah K, Giles RH, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Volpe A, Ljungberg B, Escudier B, Powles T.

Eur Urol. 2018 Dec;74(6):849-851. doi: 10.1016/j.eururo.2018.08.029. Epub 2018 Sep 7. No abstract available.

PMID:
30201510
7.

Cystic Appearance on Imaging Methods (Bosniak III-IV) in Histologically Confirmed Papillary Renal Cell Carcinoma is Mainly Characteristic of Papillary Renal Cell Carcinoma Type 1 and Might Predict a Relatively Indolent Behavior of Papillary Renal Cell Carcinoma.

Procházková K, Mírka H, Trávníček I, Pitra T, Kolár J, Roušarová M, Hošek P, Bajcurová K, Ferda J, Staehler M, Brookman May SD, Hes O, Hora M.

Urol Int. 2018 Sep 10:1-8. doi: 10.1159/000492719. [Epub ahead of print]

PMID:
30199877
8.

A new setup for the quantitative analysis of drying by the use of gas-phase FTIR-spectroscopy.

Scheepers F, Staehler A, Staehler M, Carmo M, Lehnert W, Stolten D.

Rev Sci Instrum. 2018 Aug;89(8):083102. doi: 10.1063/1.5036817.

PMID:
30184627
9.

Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Staehler M, Volpe A, Powles T.

Eur Urol. 2018 Dec;74(6):805-809. doi: 10.1016/j.eururo.2018.08.008. Epub 2018 Aug 31.

PMID:
30177291
10.

Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma.

Staehler M, Battle D, Bex A, Hammers H, George D.

Eur Urol. 2018 Dec;74(6):842-843. doi: 10.1016/j.eururo.2018.08.011. Epub 2018 Aug 28. No abstract available.

PMID:
30170873
11.

High proliferation rate and TNM-stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma.

Polifka I, Agaimy A, Herrmann E, Spath V, Trojan L, Stöckle M, Becker F, Ströbel P, Wülfing C, Schrader AJ, Barth P, Staehler M, Stief C, Hohenfellner M, Macher-Göppinger S, Höfler H, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Haferkamp A, Geppert CI, Stöhr C, Hartmann A; German Network Of Kidney Cancer.

Hum Pathol. 2018 Aug 16. pii: S0046-8177(18)30311-3. doi: 10.1016/j.humpath.2018.08.006. [Epub ahead of print]

PMID:
30121370
12.

Emphysematous pyelonephritis: Case report and literature overview.

Ziegelmüller BK, Szabados B, Spek A, Casuscelli J, Stief C, Staehler M.

Urologia. 2018 Aug;85(3):123-126. doi: 10.1177/0391560317749428. Epub 2018 Mar 26.

PMID:
30117388
13.

External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Marconi L, de Bruijn R, van Werkhoven E, Beisland C, Fife K, Heidenreich A, Kapoor A, Karam J, Kauffmann C, Klatte T, Ljungberg B, Matin S, Sjoberg D, Staehler M, Stewart GD, Tanguay S, Uzzo R, Welsh S, Wood L, Wood C, Bex A.

World J Urol. 2018 Aug 1. doi: 10.1007/s00345-018-2427-z. [Epub ahead of print]

PMID:
30069581
14.

Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry.

Goebell PJ, Staehler M, Müller L, Nusch A, Scheffler M, Sauer A, von Verschuer U, Tech S, Kruggel L, Jänicke M, Marschner N; RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma).

Clin Genitourin Cancer. 2018 Jun 27. pii: S1558-7673(18)30139-3. doi: 10.1016/j.clgc.2018.06.006. [Epub ahead of print]

15.

An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma.

Grünwald V, Eberhardt B, Bex A, Flörcken A, Gauler T, Derlin T, Panzica M, Dürr HR, Grötz KA, Giles RH, von Falck C, Graser A, Muacevic A, Staehler M.

Nat Rev Urol. 2018 Aug;15(8):511-521. doi: 10.1038/s41585-018-0034-9. Review.

PMID:
29904105
16.

Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.

Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, Febbo PG, Li R, Lin X, Valota O, Staehler M, Motzer RJ, Ravaud A.

Clin Cancer Res. 2018 Sep 15;24(18):4407-4415. doi: 10.1158/1078-0432.CCR-18-0323. Epub 2018 May 17.

PMID:
29773662
17.

Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis.

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A.

Eur Urol Focus. 2018 Mar 7. pii: S2405-4569(18)30072-5. doi: 10.1016/j.euf.2018.02.010. [Epub ahead of print]

PMID:
29525381
18.

[Epidemiology and diagnostic assessment of small renal masses].

Ziegelmüller BK, Spek A, Szabados B, Casuscelli J, Clevert DA, Staehler M.

Urologe A. 2018 Mar;57(3):274-279. doi: 10.1007/s00120-018-0585-7. Review. German.

PMID:
29460170
19.

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Escudier B, Gerletti P, Li S, Casey M, Laguerre B, Pandha HS, Pantuck AJ, Patel A, Lechuga MJ, Ravaud A.

Clin Cancer Res. 2018 Apr 1;24(7):1554-1561. doi: 10.1158/1078-0432.CCR-17-2822. Epub 2018 Jan 26.

PMID:
29374054
20.

Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).

Siva S, Louie AV, Warner A, Muacevic A, Gandhidasan S, Ponsky L, Ellis R, Kaplan I, Mahadevan A, Chu W, Swaminath A, Onishi H, Teh B, Correa RJ, Lo SS, Staehler M.

Cancer. 2018 Mar 1;124(5):934-942. doi: 10.1002/cncr.31156. Epub 2017 Dec 20.

PMID:
29266183
21.

Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer.

Powles T, Albiges L, Staehler M, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Volpe A, Ljungberg B, Bex A.

Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31001-1. doi: 10.1016/j.eururo.2017.11.016. [Epub ahead of print]

PMID:
29223605
22.

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M.

Eur Urol. 2018 Jan;73(1):62-68. doi: 10.1016/j.eururo.2017.09.008. Epub 2017 Sep 28.

PMID:
28967554
23.

Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.

Grande E, Glen H, Aller J, Argenziano G, Lamas MJ, Ruszniewski P, Zamorano JL, Edmonds K, Sarker S, Staehler M, Larkin J.

Expert Opin Drug Saf. 2017 Dec;16(12):1413-1426. doi: 10.1080/14740338.2017.1380624. Epub 2017 Sep 28. Review.

PMID:
28920492
24.

New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?

Escudier B, Staehler M.

Eur Urol. 2018 Jan;73(1):1-3. doi: 10.1016/j.eururo.2017.08.020. Epub 2017 Sep 8.

PMID:
28890247
25.

Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma.

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Staehler M, Volpe A, Powles T.

Eur Urol. 2017 May;71(5):719-722. doi: 10.1016/j.eururo.2016.11.034. Epub 2016 Dec 13.

PMID:
27986369
26.

A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.

Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A.

Eur Urol. 2017 Mar;71(3):426-436. doi: 10.1016/j.eururo.2016.11.020. Epub 2016 Dec 8. Review.

PMID:
27939075
27.

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.

Chamie K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, Jankilevich G, Kapoor A, Kopyltsov E, Staehler M, Taari K, Wainstein AJA, Pantuck AJ, Belldegrun AS.

JAMA Oncol. 2017 Jul 1;3(7):913-920. doi: 10.1001/jamaoncol.2016.4419.

28.

Clinical Usage of Different Guidelines in Routine Management, Therapy and Follow-Up of Patients with Renal Cell Cancer in Germany.

Spek A, Szabados B, Ziegelmüller B, Stief C, D'Anastasi M, Staehler M.

Urol Int. 2017;98(2):156-161. doi: 10.1159/000448435. Epub 2016 Oct 18.

PMID:
27750248
29.

Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry.

Marschner N, Staehler M, Müller L, Nusch A, Harde J, Koska M, Jänicke M, Goebell PJ; RCC Registry Group.

Clin Genitourin Cancer. 2017 Apr;15(2):e209-e215. doi: 10.1016/j.clgc.2016.08.022. Epub 2016 Sep 8.

30.

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ; S-TRAC Investigators.

N Engl J Med. 2016 Dec 8;375(23):2246-2254. Epub 2016 Oct 9.

31.

Morphological Characterization of Papillary Renal Cell Carcinoma Type 1, the Efficiency of Its Surgical Treatment.

Procházková K, Staehler M, Trávníček I, Pitra T, Eret V, Ürge T, Eberlová L, Roušarová M, Hošek P, Chudáček Z, Ferda J, Hes O, Hora M.

Urol Int. 2017;98(2):148-155. doi: 10.1159/000448434. Epub 2016 Sep 30.

PMID:
27684070
32.

Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer.

Hellbach K, Sterzik A, Sommer W, Karpitschka M, Hummel N, Casuscelli J, Ingrisch M, Schlemmer M, Graser A, Staehler M.

Eur Radiol. 2017 Jun;27(6):2532-2537. doi: 10.1007/s00330-016-4597-7. Epub 2016 Sep 27.

PMID:
27678131
33.

European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy.

Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Volpe A, Bex A.

Eur Urol. 2016 Nov;70(5):705-706. doi: 10.1016/j.eururo.2016.06.009. Epub 2016 Jun 24.

PMID:
27349614
34.

Author Reply.

Ljungberg B, Hedin O, Lundstam S, Warnolf Å, Mandahl Forsberg A, Hjelle KM, Stief CG, Borlinghaus C, Beisland C, Staehler M.

Urology. 2016 Jul;93:122-3. doi: 10.1016/j.urology.2016.01.039. Epub 2016 May 4. No abstract available.

PMID:
27155982
35.

Long-term outcomes after resection of Stage IV cavoatrial tumour extension using deep hypothermic circulatory arrest.

Dashkevich A, Bagaev E, Hagl C, Pichlmaier M, Luehr M, von Dossow V, Stief C, Brenner P, Staehler M.

Eur J Cardiothorac Surg. 2016 Nov;50(5):892-897. Epub 2016 Apr 26.

PMID:
27122607
36.

Nephron Sparing Surgery Associated With Better Survival Than Radical Nephrectomy in Patients Treated for Unforeseen Benign Renal Tumors.

Ljungberg B, Hedin O, Lundstam S, Warnolf Å, Mandahl Forsberg A, Hjelle KM, Stief CG, Borlinghaus C, Beisland C, Staehler M.

Urology. 2016 Jul;93:117-23. doi: 10.1016/j.urology.2016.01.037. Epub 2016 Mar 24.

PMID:
27017902
37.

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.

Powles T, Lackner MR, Oudard S, Escudier B, Ralph C, Brown JE, Hawkins RE, Castellano D, Rini BI, Staehler MD, Ravaud A, Lin W, O'Keeffe B, Wang Y, Lu S, Spoerke JM, Huw LY, Byrtek M, Zhu R, Ware JA, Motzer RJ.

J Clin Oncol. 2016 May 10;34(14):1660-8. doi: 10.1200/JCO.2015.64.8808. Epub 2016 Mar 7.

38.

Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma.

Siva S, Ellis RJ, Ponsky L, Teh BS, Mahadevan A, Muacevic A, Staehler M, Onishi H, Wersall P, Nomiya T, Lo SS.

Future Oncol. 2016 Mar;12(5):637-45. doi: 10.2217/fon.16.2. Epub 2016 Feb 3.

PMID:
26837701
39.

Renal Pseudoaneurysms and Arteriovenous Fistulas as a Complication of Nephron-Sparing Partial Nephrectomy: Technical and Functional Outcomes of Patients Treated With Selective Microcoil Embolization During a Ten-Year Period.

Strobl FF, D'Anastasi M, Hinzpeter R, Franke PS, Trumm CG, Waggershauser T, Staehler M, Clevert DA, Reiser M, Graser A, Paprottka PM.

Rofo. 2016 Feb;188(2):188-94. doi: 10.1055/s-0041-110136. Epub 2016 Jan 12.

40.

Dual energy can accurately differentiate uric acid-containing urinary calculi from calcium stones.

Spek A, Strittmatter F, Graser A, Kufer P, Stief C, Staehler M.

World J Urol. 2016 Sep;34(9):1297-302. doi: 10.1007/s00345-015-1756-4. Epub 2016 Jan 9.

PMID:
26749082
41.

Intravoxel Incoherent Motion Magnetic Resonance Imaging in Partially Nephrectomized Kidneys.

Schneider MJ, Dietrich O, Ingrisch M, Helck A, Winter KS, Reiser MF, Staehler M, Casuscelli J, Notohamiprodjo M.

Invest Radiol. 2016 May;51(5):323-30. doi: 10.1097/RLI.0000000000000244.

PMID:
26713966
42.

Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus.

Lardas M, Stewart F, Scrimgeour D, Hofmann F, Marconi L, Dabestani S, Bex A, Volpe A, Canfield SE, Staehler M, Hora M, Powles T, Merseburger AS, Kuczyk MA, Bensalah K, Mulders PF, Ljungberg B, Lam TB.

Eur Urol. 2016 Aug;70(2):265-80. doi: 10.1016/j.eururo.2015.11.034. Epub 2015 Dec 23. Review.

PMID:
26707869
43.

Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.

Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Volpe A, Bex A.

Eur Urol. 2016 Jan;69(1):4-6. doi: 10.1016/j.eururo.2015.10.017. Epub 2015 Oct 24.

PMID:
26508312
44.

Parametric imaging of clear cell and papillary renal cell carcinoma using contrast-enhanced ultrasound (CEUS).

Rübenthaler J, Reimann R, Hristova P, Staehler M, Reiser M, Clevert DA.

Clin Hemorheol Microcirc. 2015 Oct 16;63(2):89-97. doi: 10.3233/CH-152010.

PMID:
26484712
45.

Characterization of histological subtypes of clear cell renal cell carcinoma using contrast-enhanced ultrasound (CEUS).

Reimann R, Rübenthaler J, Hristova P, Staehler M, Reiser M, Clevert DA.

Clin Hemorheol Microcirc. 2015 Oct 16;63(1):77-87. doi: 10.3233/CH-152009.

PMID:
26484711
46.

Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy.

Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, Bex A, Bensalah K, Canfield SE, Hora M, Kuczyk MA, Merseburger AS, Mulders PFA, Powles T, Staehler M, Ljungberg B, Volpe A.

Eur Urol. 2016 Apr;69(4):660-673. doi: 10.1016/j.eururo.2015.07.072. Epub 2015 Aug 29. Review.

PMID:
26323946
47.

[Cross-sectional imaging evaluation of renal masses].

Nuhn P, Sterzik A, Stief CG, Staehler M, D'Anastasi M.

Urologe A. 2015 Jul;54(7):972-82. doi: 10.1007/s00120-015-3866-4. German.

PMID:
26162273
48.

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.

Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard JC, Joly F, Guy L, Ravaud A, Azzouzi AR, Gravis G, Chevreau C, Zini L, Lang H, Pfister C, Lechevallier E, Fais PO, Berger J, Vayleux B, Roupret M, Audenet F, Descazeaud A, Rigaud J, Machiels JP, Staehler M, Salomon L, Ferriere JM, Kleinclauss F, Bensalah K, Patard JJ.

Urol Oncol. 2015 Aug;33(8):339.e9-15. doi: 10.1016/j.urolonc.2015.05.014. Epub 2015 Jun 16.

PMID:
26087971
49.

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.

Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Flörcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS.

Eur Urol. 2015 Nov;68(5):837-47. doi: 10.1016/j.eururo.2015.04.017. Epub 2015 May 4.

50.

Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study.

Bergmann L, Kube U, Doehn C, Steiner T, Goebell PJ, Kindler M, Herrmann E, Janssen J, Weikert S, Scheffler MT, Schmitz J, Albrecht M, Staehler M.

BMC Cancer. 2015 Apr 18;15:303. doi: 10.1186/s12885-015-1309-7.

Supplemental Content

Loading ...
Support Center